UBC Announces Real-World Evidence Generation Initiative

Article

New initiative from late-stage research and patient-support services organization aims to accelerate COVID-19 vaccine development.

UBC, a late-stage research and patient-support services organization, is announcing an offering to harness the power of real-world data (RWD) for rapid generation of insights into the safety and effectiveness of COVID-19 vaccines.

As vaccine manufacturers prepare for post authorization surveillance initiatives to generate outcome evidence in real-world settings, the ability to rapidly automate analysis of large-scale representative databases is essential.

The real-world data analyses will be made possible through a collaboration with companies such as global healthcare technology company Cerner Corporation and its Cerner Real-World Data, a national, de-identified data set including approximately 92 million patients from 90 health systems.

The integration of UBC’s analytical tools and epidemiologic expertise with real-world data enables researchers to customize and automate insights from the front lines of vaccine and healthcare delivery.

For more information, click here.

Related Videos
Jason Tate, FSP Talent Strategy Lead, PPD, part of Thermo Fisher Scientific
Related Content